Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic

Subscriber access provided by UNIVERSITY OF CONNECTICUT

Bioactive Constituents, Metabolites, and Functions

Prebiotic mannan-oligosaccharides augment the hypoglycemic effects of metformin in correlation with modulating gut microbiota Jialin Zheng, Heng Li, Xiaojuan Zhang, Min Jiang, Chunqin Luo, Zhenming Lu, Zheng-Hong Xu, and Jin-Song Shi J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.8b00829 • Publication Date (Web): 27 Apr 2018 Downloaded from http://pubs.acs.org on June 4, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 34

Journal of Agricultural and Food Chemistry

Prebiotic mannan-oligosaccharides augment the hypoglycemic effects of metformin in correlation with modulating gut microbiota §

Jialin Zheng†, Heng Li*,†, Xiaojuan Zhang‡, Min Jiang†, Chunqin Luo , Zhenming Lu‡, Zhenghong Xu‡,#, Jinsong Shi*,† †

Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School

of Pharmaceutical Science, Jiangnan University, 1800 Lihu Avenue, Wuxi 214122, China ‡

National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University,

1800 Lihu Avenue, Wuxi 214122, China §

Chengdu Yongan Yuanhe Biotechnology Co. Ltd., 5th Tianfu Street, Chengdu 611630, China

#

School of Biotechnology, Jiangnan University, 1800 Lihu Avenue, Wuxi 214122, China

*

Corresponding author, Tel: +86-510-85328177; Fax: +86-510-85328177; E-mail:

[email protected], [email protected]

1

ACS Paragon Plus Environment


1

ABSTRACT

2

Type 2 diabetes (T2D) induced by obesity and high-fat diet is significantly associated with gut

3

microbiota dysbacteriosis. Due to the first line clinical medicine of metformin has several

4

intestinal drawbacks, combination usage of metformin with a prebiotic of konjac

5

mannan-oligosaccharides (MOS) was conceived and implemented aiming to investigate whether

6

there was some intestinal synergetic effects and how MOS would function. Composite treatment

7

of metformin and MOS demonstrated synergistic effects on ameliorating insulin resistance and

8

glucose tolerance, and repairing islet and hepatic histology. In addition, MF+MOS altered the gut

9

community composition and structure by decreasing the relative abundances of family

10

Rikenellaceae and order Clostridiales while increasing an unnamed OTU05945 of family S24-7,

11

Akkermansia muciniphila, and Bifidobacterium pseudolongum. The present study suggested that

12

usage of MOS could augment the hypoglycemic effects of metformin in association with gut

13

microbiota modulation, which could provide references for further medication.

14 15

KEYWORDS: konjac mannan-oligosaccharides (MOS); gut microbiota; type 2 diabetes;

16

metformin

17

2 Environment ACS Paragon Plus

Page 2 of 34

Page 3 of 34

18


INTRODUCTION

19

Diabetes has become a severe health issue accompanied by obesity, sedentary lifestyles, and

20

population aging.1 It is estimated that global diabetic population is rapidly growing from 415

21

million in 2015 to 642 million by 2040,1 within which 90% above are type 2 diabetes patients

22

characterized by insulin resistance and impaired glucose tolerance.2 This situation imposes a

23

great socio-economic burden on public health, and meanwhile hastens new intervention

24

mechanisms and therapeutic strategies to come out.

25

Gut microbiota plays an important role in health. It is causally concerned with the onset or

26

progression of many diseases, including cancer, inflammatory bowel disease, and metabolic

27

disease.3 Accumulating evidences indicate that gut microbiota is strongly associated with T2D

28

development.4 Qin et al found that patients with T2D were characterized by a moderate degree of

29

gut microbial dysbiosis.5 The composition of the microbiome differed between diabetic and

30

normal individuals. Specifically, diabetes was associated with a decrease in the abundance of

31

some universal butyrate-producing bacteria and an increase in various opportunistic pathogens.

32

In addition, a study investigating 277 non-diabetic Danish individuals and 75 T2D Danish

33

patients showed that human gut microbiome impacted the serum metabolome and associates with

34

insulin resistance.6 On the basis, gut microbiota has been developed as a new therapeutic target

35

for diabetes and other disorders associated with metabolic syndrome. Fecal microbiota

36

transplantation (FMT) has provided the most direct evidences. Taken for examples, FMT from

37

lean donors to obese patients with metabolic syndrome improved insulin sensitivity notably.7

38

Meanwhile, diets supplemented with probiotics and prebiotics are considered to be beneficial in

39

diabetes mellitus management.8



40

As a first line clinical medicine for T2D, metformin performed significant effects on inhibition

41

of hepatic glucose production, promotion of glucose uptake increase9, and alleviation of

42

insulitis10. Recent studies in mice showed that metformin could also influence gut microbiota and

43

corresponding metabolic pathways11. Nevertheless, metformin treatment is associated with a

44

number of intestinal side effects, such as adverse lipid metabolism, vitamin B12 deficiency, and

45

digestive disorders.12,13 However, these drawbacks could be alleviated by adding prebiotics to

46

promote intestinal beneficial bacteria proliferation and vitamin B supply.14 Clinical data also

47

show that reasonable dietary fiber intake and diet regulation can control obesity and T2D, which

48

was even more effective and safer than metformin.15 As a result, a proposal that combination of

49

prebiotics or probiotics with metformin to treat diabetes had been developed.16

50

Konjac mannan oligosaccharides (MOS) is consisted of β-D-mannose and β-D-glucose

51

residues jointed together in 1→4 linkages.17 It is generally obtained through depolymerization of

52

Konjac glucomannan (KG), which is an essential polysaccharide and the main component of the

53

roots and tubers of Amorphophallus konjac plant.18 KG and MOS cannot be hydrolyzed by

54

digestive enzymes in human upper gastrointestinal tract. It has already been verified that KG

55

performed prebiotic effects in alleviating hypercholesterolemia and hyperglycemia.19,20 In a

56

randomized cross over study including 22 T2D patients, it was found that the KG supplement

57

improved blood lipid levels and alleviated the elevated glucose levels in diabetic subjects.21

58

Evidences also showed that konjac glucomannan hydrolysates could potentially improve gut

59

health by promoting the growth of beneficial bacteria and suppressing the pathogenic ones, and

60

seemed to lower the blood glucose and cholesterol in mice.22 In addition, with the ability to bind

61

and limit the colonization of gut pathogens, MOS has proven to be an effective solution for

62

antibiotic-free diets, as well as applying in immunity and digestion and food ingredients.23


Page 4 of 34

Page 5 of 34


63

Owing to the superiorities of MOS in prebiotic properties and dissolvability, it is worth

64

investigating in detail whether there is some synergetic effects for composite treatment of MOS

65

and metformin and how MOS would function therein.

66

Consequently, experiments with MOS alone and its combination with metformin treatments

67

were both conceived and conducted on a T2D model in mice in this study. The biochemical

68

indexes were first examined to verify whether MOS possessed the hypoglycemic effects and

69

whether there was a synergistic effect between MOS and metformin. Gut microbiota was then

70

analyzed by 16S rRNA gene sequencing to elucidate the potential possible mechanism.

71

MATERIALS AND METHODS

72

Materials and Animals. MOS (average molecular weight ca. 1000 Da, mole ratio of glucose

73

to mannose 1:1.2, degree of polymerization 2-6) was supplied from Yongan Yuanhe

74

Biotechnology Co., Ltd (Chengdu, China). Metformin and streptozotocin (STZ) was purchased

75

from Sigma-Aldrich (St. Louis, MO, USA). High-fat diet (#TP23300, fat 60.0%, carbohydrate

76

20.6% protein 19.4%) and normal control diet (#TP23302, fat 10.0%, carbohydrate 71.0%,

77

protein 19.0%) were supplied by TROPHIC Animal Feed High-Tech Co., Ltd. Glucometer and

78

strips were purchased from Roche Diagnostics GmbH (Mannheim, Germany). Glycosylated

79

hemoglobin (HbA1c) assay kit and insulin ELISA kits was purchased from Nanjing Jiancheng

80

Bioengineering Institute (Nanjing, China). QIAamp DNA Stool minikit was obtained from

81

Qiagen (Hilden, Germany).

82

A total of 88 three-week-old male C57BL/6J mice were purchased from SLAC laboratory

83

(Shanghai, China) and housed at constant temperature of 25 °C and relative humidity of 55 ± 5%

84

under an artificial 12 h light/darkness cycle with ad libitum access to chow diet and water.

85

Animal experiments were approved and performed in accordance with the guidelines of



86

Institutional

Animal

Care

87

No20170505-20170609[57]).

and

Use

Committee

of

Page 6 of 34

Jiangnan

University

(JN.

88

Type 2 Diabetes Model Construction. After being acclimated for a week, 80 C57BL/6J mice

89

were used to establish the diabetic models, which were first fed with high fat diet for 4 weeks

90

and then injected with STZ (30 mg/kg, dissolved in 0.01 M sodium citrate buffer, pH 4.4)

91

intraperitoneally for 7 consecutive days.24 During the next 4 weeks, fasting blood glucose (FBG)

92

was detected every week. Those mice (80) whose blood glucose were 11.1 mmol/L above were

93

considered as diabetic rats and ready for further pharmacological studies.

94

Grouping and Treatment Experiment Design. Three kinds of treatments consisting of

95

metformin alone (MF), MOS and combination of the above two (MF+MOS) were employed and

96

compared. 80 diabetic mice were randomly divided into 10 groups (8 mice per group) and treated

97

as per the following specifications. Diabetic model control group (MC): diabetic mice treated

98

with saline in a matched volume (10 mL/kg), MF treatment groups: diabetic mice administered

99

with MF respectively at high (200 mg/kg/day, MFH) and low dosages (75 mg/kg/day, MFL),

100

MOS treatment groups: diabetic mice treated with MOS separately at high (8 g/kg/day, MOSH),

101

medium (4 g/kg/day, MOSM) and low (2 g/kg/day, MOSL) dosages, composite treatment of MF

102

and MOS groups: MF treatment groups at two dosages and MOS treatment groups at high and

103

medium dosages were selected and combined in pairs randomly. Then there came out four

104

composite treatment groups: MFH+MOSH, MFH+MOSM, MFL+MOSH, and MFL+MOSM. A

105

normal group (NC, n = 8) treated with saline in a same volume was also set for control. All

106

treatments were given orally consecutively for 5 weeks. Body weight, food/water intake and

107

FBG were detected and monitored weekly. At the end of experiments, all mice were

108

anaesthetized and humanely sacrificed by cervical dislocation after overnight fasting. Blood


Page 7 of 34


109

samples were collected from mice orbit and then quickly separated at 4 oC to obtain plasma and

110

red blood cells, which were stored at -80 oC. For histological analysis, pancreases and the right

111

lobe of livers were fixed in 10% neutral formalin at room temperature. Fresh feces samples of

112

different treatments were collected for the last week and stored at -80 °C.

113

Oral Glucose Tolerance Tests (OGTT). At the last week, mice were fasted for 12 h and then

114

gavaged with glucose solution at the dose of 1 g/kg. Tail vein blood samples were collected for

115

blood glucose concentration detection with a glucose meter at 0, 30, 60, and 120 min. The results

116

were expressed as an integrated area under glucose concentration-time curve (AUC).

117

Biochemical Parameters. Hemoglobin A1c (HbA1c) in red blood cells was estimated by

118

diagnostic kits according to the instruction of the kits. HbA1c was calculated as optical density

119

value per 10 g hemoglobin. Plasma insulin was estimated using ELISA kits according to the

120

manufacturer’s instructions. Homeostasis assessment of insulin resistance (HOMA-IR) was then

121

calculated.

122

Histological Examination of Pancreas and Livers. After being dehydrated with graded

123

alcohol series, pancreas and liver samples were embedded in paraffin and cut into sections.

124

Sections with 4 µm thickness were stained with hematoxylin and eosin and evaluated the related

125

indicators under light microscope.

126

Sequencing and Sequence Data Analysis. Total fecal bacterial genome DNA was extracted

127

from the faeces using a QIAamp DNA Stool minikit following the manufacturer’s instructions.

128

The V3-V4 region of the 16S rRNA gene was amplified using forward primer 338F and reverse

129

primer 806R.25 After being purified and recovered, PCR products were barcoded and quantified

130

using a QuantiFluor-ST Fluorometer (Promega, USA) and were pooled for sequencing.



131

Sequencing was performed on the Illumina®MiSeq sequencer (Illumina, San Diego, CA, USA)

132

by Majorbio Bio-pharm Technology Co., Ltd. (Shanghai, China).

133

QIIME 1.9.1 was used to process the resulting sequence data. Briefly, high quality (quality

134

value > 25) sequence data derived from the sequencing process were demultiplexed. USEARCH

135

was used to obtain operational taxonomic units (OTUs) with 97% sequence similarity. Principal

136

Coordinate Analysis (PCoA) and Unweighted Pair Group Method with Arithmetic mean

137

(UPGMA) Clustering tree were used to assess the variation between experimental groups (beta

138

diversity). Alpha diversity was calculated for all the samples. Analysis of similarities (ANOSIM)

139

and Pearson correlation analysis was conducted by Phylogenetic Investigation of Communities

140

by Reconstruction of Unobserved States (PiCRUSt, http://picrust.github.com) and performed to

141

predict the abundances of functional gene categories on KEGG pathway database.

142

Statistical Analysis. Data were expressed as mean ± standard error of the mean.26 The

143

significance of difference among diet groups was analyzed by one-way ANOVA followed by

144

Tukey’s post hoc test. Probability values lower than 0.05 were taken to indicate statistical

145

significance. All analyses were performed using GraphPad Prism version 7.0. A non-parametric

146

statistical t test was conducted by ANOSIM to determine statistically significant changes (p

Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic

Recommend Documents